Detecting clinically significant disease among PIRADS category 3 lesions may be improved by incorporating clinical parameters into risk stratification algorithms.

Detecting clinically significant disease among PIRADS category 3 lesions may be improved by incorporating clinical parameters into risk stratification algorithms.

ORION CORPORATIONÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂ PRESS RELEASE ÂÂÂÂÂÂÂÂÂÂÂÂÂÂ 3 APRIL 2018 at 10.30 EESTÂÂÂÂÂÂ Â Â Status update of the Phase III ARAMIS clinical trial with darolutamide in patients with nonmetastatic castrationresistant prostate cancer Â...

By taking Zytiga with a lowfat meal could decrease the daily dose and prevent digestive issues...The post Taking a standard prostate cancer drug with food boosts impact appeared first on

SummaryMetaStat Inc MetaStat is a biotechnology company that discovers and develops personalized diagnostic and therapeutic treatment solutions for cancer patients. The company develops therapeutic product candidates based on novel approach that offers int...

Cold Spring Harbor Laboratory Scientists at CSHL have discovered that cells lacking the tumorsuppressor protein PTEN a feature of many cancers especially prostate cancer are particularly vulnerable to drugs that impair their energyproducing mitochondria....

Ohio State University Men on hormone therapy for prostate cancer may benefit significantly from hitting the gym with fellow patients and choosing more veggies and fewer cheeseburgers a new study suggests.

MDxHealth SA molecular diagnostics for cancer grossed 36mm $44mm through the private placement of 9.99mm new shares at 3.60 a 5 discount. Proceeds will support continued development of SelectMDx prostate cancer biopsy test; commercialization activities for...

MedPage Today Docetaxel abiraterone plus ADT for nonCRPC

Project Data Sphere LLC an independent notforprofit initiative of the CEO Roundtable on Cancer Inc.s Life Sciences Consortium established to share integrate and analyze historical cancer data to accelerate research has named B...

SummaryOncogenex Pharmaceuticals Inc OncoGenex formerly known as Sonus Pharmaceuticals Inc is a drug discovery and development company that develops and commercializes therapies and mechaisms for addressing treatment resistance in cancer patients. The comp...

Prostate cancer is the second most common cancer in men and the fifth leading cause of death from cancer in men worldwide according to 2012 numbers. While several viable treatment options for prostate cancer exist many men affected with prostate cancer wil...

Advaxis Inc.ÂNASDAQADXS a latestage biotechnology company focused on the discovery development and commercialization of immunotherapy products announces that The American Society of Clinical Oncology has accepted the abstract ...

A draft local coverage determination was granted by Palmetto GBA a Medicare contractor to Epic Sciences and Genomic Health More

A new study finds that the prostate cancer drug Zytiga is more effective as well as cheaper when taken with food as opposed to on an empty stomach.

University of Toronto University of Toronto researchers developed a liquid biopsy technology to improve prostate cancer treatment.

SummaryVolitionRX Ltd VolitionRX is a medical equipment provider that develops diagnostics tests for cancer and other conditions. The company develops Nucleosomics a platform technology used for measurement and identification of nucleosomes in the blood. I...

SummaryMenoGeniX Inc MenoGeniX is a biopharmaceutical company that develops treatment for menopausal women and cancer patients. The company provides pipeline product portfolio such as MNGX100 is under Phase 1b human clinical trial. Its therapeutic agents a...

Methionine Aminopeptidase 2 Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18 Pipeline Review H1 2018SummaryAccording to the recently published report 'Methionine Aminopeptidase 2...

Edouard J. Trabulsi MD discusses emerging multimodal treatment approaches for patients with locally advanced prostate cancer.